Challenges and strategies: The immune responses in gene therapy

@article{Zhou2004ChallengesAS,
  title={Challenges and strategies: The immune responses in gene therapy},
  author={Hai-sheng Zhou and De-Pei Liu and Chih-Chuan Liang},
  journal={Medicinal Research Reviews},
  year={2004},
  volume={24}
}
The host immune responses, including T lymphocytes mediated immune response and humoral immune responses are the important parts of the challenges in gene therapy. There are some potential immunostimulants in gene delivery systems, such as viral and non‐viral vectors. Viral gene products, transgene products, viral proteins derived from viral particles required by dead‐end infection, and CpG DNA in plasmid may play important roles in inducing the host immune responses when foreign genes are… 
Hurdles and Improvements in Therapeutic Gene Transfer for Cancer
TLDR
The results indicate that the gene delivery can induce undesired immune responses in target cells and thus may represent a barrier against efficient therapeutic gene transfer.
Transcriptional Targeting and MicroRNA Regulation of Lentiviral Vectors
Evolving lessons on nanomaterial-coated viral vectors for local and systemic gene therapy.
TLDR
Various chemical modification strategies to enhance the therapeutic efficacy of viral vectors delivered either locally or systemically are discussed, highlighting the salient features of various nanomaterial-coated viral vectors and their prospects and directions for future research.
The immune response to lentiviral-delivered transgene is modulated in vivo by transgene-expressing antigen-presenting cells but not by CD4+CD25+ regulatory T cells.
TLDR
The data indicate that antitransgene immune response can be modulated by transgene-expressing APCs possibly through deletion of effector T cells, and demonstrate that neither increasing the endogenous pool of natural Tregs nor transferring nTregs selected in a transGene- expressing thymus can modulate the immune response and mediate sustained transgenes expression.
Investigation of the activation of tumour-specific immune responses by gene therapy strategies using a model tumour antigen
TLDR
Findings indicate that NR/CB1954-mediated tumour cell death is a weakly immunogenic process that facilitates short-term antitumour CD8\(^+\) T cell responses.
Novel Nonviral Vectors Target Cellular Signaling Pathways: Regulated Gene Expression and Reduced Toxicity
TLDR
Hopes are provided that free ligand can be used to effectively mediate cellular processes to overcome some of the obstacles limiting the success of gene therapy as well as to develop more efficient nonviral vectors.
Towards effective non-viral gene delivery vector
TLDR
Minimal vectors, which are devoid of the bacterial backbone and consist exclusively of the eukaryotic expression cassette, demonstrate better performance in terms of expression levels, bioavailability, transfection rates and increased therapeutic effects.
TOWARDS THE RATIONAL DESIGN AND APPLICATION OF POLYMERS FOR GENE THERAPY: INTERNALIZATION AND INTRACELLULAR FATE
TLDR
The overall goal of this work is to contribute to the design and application of novel nanoparticles for gene delivery and offer insight into the engineering of novel polyplexes.
Barriers and recent advances in non-viral vectors targeting the lungs for cystic fibrosis gene therapy
TLDR
This review paper was conduct to highlight the barriers faced by non-viral vectors when carrying a genetic payload to the lungs and the investigation of the strategies and different types of modifications targeted toward the improvement of the efficiency of non-Viral vectors.
Lentiviral vectors for regulated and liver directed gene therapy
TLDR
Data suggest that the PreS1 peptide is involved in viral attachment to the cell surface, and represents a potential approach for the targeting of lentiviral vectors to specific cell types.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 88 REFERENCES
Improvements in gene therapy: averting the immune response to adenoviral vectors.
TLDR
Despite considerable progress over the past decade in the generation of gene transfer systems with reduced immunogenic properties, the remaining immunogenicity of many gene therapy vectors is still the major hurdle, preventing their frequent application in clinical trials.
Designing gene therapy vectors: avoiding immune responses by using tissue-specific promoters
TLDR
It is shown thatHBsAg-specific humoral or cell-mediated responses are not induced in mice when the muscle-specific human muscle creatine kinase promoter is used in place of the ubiquitous cytomegaloviral promoter to drive expression of HBsAg.
Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer.
TLDR
Induction of immune tolerance to a secreted human coagulation factor IX (hF.IX) antigen by adeno-associated viral gene transfer to the liver is demonstrated, supporting the relevance of these data for treatment of hemophilia B and other genetic diseases.
Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo.
TLDR
It is confirmed that B cell-mediated events do not participate in destruction of hepatocytes in vivo, despite the production of virus- and beta-gal-specific antibodies, which confirm the hypothesis that viral gene expression elicits host responses that contribute to the problem of transgene instability.
Molecular basis of the inflammatory response to adenovirus vectors
TLDR
An understanding of the innate response to adenovirus vectors is essential to overcome the last remaining hurdle to improve the safety and effectiveness of these agents.
Cellular immune response to adenoviral vector infected cells does not require de novo viral gene expression: implications for gene therapy.
TLDR
It is proposed that cells infected with RDAd vectors present antigens for recognition by class 1 major histocompatibility complex-restricted cytotoxic T lymphocytes by a mechanism that does not require viral replication or de novo protein synthesis.
Promoter Attenuation in Gene Therapy: Interferon-γ and Tumor Necrosis Factor-α Inhibit Transgene Expression
TLDR
The data indicate that the cytokines interferon-γ (IFN-γ) and tumor necrosis factor-α (TNF-α) inhibit transgene expression from certain widely used viral promoters/enhancers delivered by adenoviral, retroviral or plasmid vectors in vitro.
Effect of immune response on gene transfer to the lung via systemic administration of cationic lipidic vectors.
TLDR
It is reported that cationic lipid-protamine-DNA complexes, but not each component alone, can induce a high level of cytokine production, including interferon-γ and tumor necrosis factor-α, and it is demonstrated that LPD administration triggers apoptosis in the lung, a phenomenon that may be mediated in part by the two cytokines.
Promoter attenuation in gene therapy: interferon-gamma and tumor necrosis factor-alpha inhibit transgene expression.
TLDR
Standard gene therapy vectors in current use may be improved by altering cytokine-responsive regulatory elements by determining the mechanisms involved in cytokines-regulated vector gene expression to improve the understanding of the cellular disposition of vectors for gene transfer and gene therapy.
Induction of immunity to antigens expressed by recombinant adeno-associated virus depends on the route of administration.
TLDR
A possible role for rAAV in the immunotherapy of malignancies and viral infections is suggested, although induced antibody responses to AAV may limit its ability to be administered for repeated vaccinations.
...
1
2
3
4
5
...